MariMed (MRMD) Schedules Q2 2026 Earnings Release for August 12 with Management Call on August 13

MariMed Confirms August 12 as Date for Q2 2026 Financial Results

On July 15, 2026, MariMed Inc. confirmed via Globe Newswire that it will report its Q2 2026 financial results after North American markets close on August 12, 2026. This announcement provides investors with a clear timeline to prepare for the company’s quarterly financial disclosure and analysis.

Releasing results post-market close is standard practice, allowing investors and analysts time to review the data before pre-market trading begins. MariMed’s scheduling of an earnings call the next morning enables stakeholders to engage directly with management and ask informed questions.

Details for August 13 Conference Call and Webcast Access

The management conference call will commence at 8:00 a.m. EDT on August 13, 2026, the morning after the earnings release. A live webcast will be accessible via MariMed’s Investor Relations website. While specific dial-in numbers or access codes were not provided in the announcement, investors are encouraged to visit the Investor Relations page for details.

The company also confirmed that a replay of the call will be available on the Investor Relations website following the live event, allowing those unable to attend in real time to listen to management’s commentary at their convenience. The duration of replay availability was not specified.

MariMed’s Multi-State Cannabis Operations Ahead of Q2 Report

MariMed operates as a prominent multi-state cannabis operator encompassing cultivation, production, and retail. The company manages 13 Thrive Dispensary retail locations across five states, making it one of the more geographically diversified cannabis retailers in its markets. MariMed is recognized for developing and managing advanced cultivation, production, and retail facilities.

This extensive footprint means quarterly results reflect performance across multiple regulatory environments, each with distinct tax, licensing, and competitive factors. Investors will likely seek management insights on how individual state markets performed during Q2 2026.

Branded Cannabis Portfolio Featuring Betty's Eddies, Nature's Heritage, and More

In addition to its dispensary network, MariMed is a consumer packaged goods company with an award-winning cannabis brand portfolio, including Betty's Eddies™, Bubby's Baked™, InHouse™, Nature's Heritage™, and Vibations™. These brands are nationally recognized and crafted with an emphasis on quality and innovation.

Investors will be attentive to how these proprietary brands perform relative to retail revenues in the upcoming Q2 report. A strong branded goods segment may present different margin dynamics compared to retail sales. No preliminary revenue or profitability figures were provided in this announcement; such details will be disclosed with the August 12 report.

Dual Listings on CSE and OTCQB Facilitate Investor Access

MariMed trades on the Canadian Securities Exchange (CSE) and the OTCQB Venture Market in the U.S., both under the ticker MRMD. This dual listing is common among U.S.-based cannabis companies seeking access to Canadian capital markets, which have historically been more accommodating to cannabis sector listings.

The CSE listing provides Canadian investors access, while the OTCQB offers a regulated U.S. trading venue. Investors on both exchanges will closely monitor the August 12 earnings release amid ongoing sector challenges such as pricing pressure, regulatory complexity, and illicit market competition.

Q2 2026 Earnings Cycle Insights for Cannabis Market Observers

MariMed’s Q2 2026 earnings announcement is part of the broader mid-year cannabis sector reporting cycle covering April through June. Analysts track this period closely for trends in wholesale pricing, retail traffic, and the effects of state policy changes on licensed operators.

With its dual role as a branded CPG operator and retail dispensary chain, MariMed’s results may provide a detailed view of consumer demand trends during the spring season. The scheduling announcement does not include financial guidance or forward-looking statements.

Thrive Dispensary Network Spanning Five States

MariMed’s 13 Thrive Dispensary locations across five states represent a key revenue source. The company highlights its reputation for exceptional customer service at these sites, though no specific sales or customer metrics were disclosed.

Retail dispensary performance varies widely based on local market conditions, including the maturity of adult-use programs, licensing activity, and competition from licensed and illicit operators. Investors will watch for management commentary on these trends during the August 13 call.

Replay Availability Enhances Access for Global Investors

The availability of a call replay on MariMed’s Investor Relations website extends the earnings event’s accessibility to investors worldwide, accommodating different time zones and analysts covering multiple companies.

The announcement does not specify whether the replay will be audio, transcript, or both, nor the length of availability. Investors should consult MariMed’s Investor Relations site for webcast and replay access details ahead of August 13.

No Preliminary Financial Data or Guidance in Announcement

This scheduling notice solely confirms the Q2 2026 results release and management call dates. It does not include any preliminary financial data, revenue forecasts, earnings guidance, or operational updates for Q2 2026.

Key financial metrics such as revenue, net income or loss, adjusted EBITDA, and gross margin will be disclosed after market close on August 12, 2026. The immediate market reaction to this announcement was not evident from available information.

MariMed’s Commitment to Growth and Industry Leadership

MariMed describes itself as a company dedicated to driving growth and setting new standards in the cannabis industry. It emphasizes its dual focus on branded consumer goods and retail dispensary operations, with brands and facilities recognized for excellence.

Whether the Q2 2026 results will confirm this growth trajectory will be a key focus for investors and analysts when the financials are released on August 12. This scheduling announcement provides no operational insights; the full financial disclosure and subsequent management commentary will be critical for assessing MariMed’s Q2 2026 performance.